Pfizer sued in US over contraceptive that women say caused brain tumours

Pfizer faces significant legal exposure from a growing class-action lawsuit, now consolidating over 1,300 cases, alleging its Depo-Provera contraceptive caused brain tumors due to inadequate warnings. This litigation, projected to involve 5,000-10,000 plaintiffs and potentially billions in damages, is bolstered by a March 2024 study linking the drug to a 5.6-fold increased meningioma risk. A key hearing on Monday will test Pfizer's pre-emption defense, claiming FDA rejection of a warning, while plaintiffs counter the request was insufficient; this situation also prompts investigations into potential shareholder fiduciary duty breaches.

Analysis

Pfizer (PFE) faces a significant and escalating legal liability stemming from a class-action lawsuit alleging its contraceptive, Depo-Provera, caused brain tumors. The litigation has rapidly expanded, tripling to over 1,300 consolidated cases since May, with projections suggesting a potential plaintiff pool of 5,000 to 10,000 and a financial exposure of several billion dollars. This legal challenge is substantiated by scientific evidence, including a March 2024 British Medical Journal study that identified a 5.6-fold increased risk of intracranial meningioma with prolonged use of the drug's active ingredient. A pivotal court hearing will test Pfizer's key pre-emption defense, where the company argues the FDA rejected its attempt to add a warning label. The outcome of this hearing, focused on five pilot cases, will serve as a critical indicator of Pfizer's ability to shield itself from liability. Compounding this issue is a separate investigation into potential breaches of fiduciary duty by Pfizer's board, introducing a governance-related risk that could precipitate shareholder legal action. The extremely negative sentiment signal (-0.9 for PFE) underscores the market's perception of this material overhang.

Key Decisions for Investors

• Investors should closely monitor the outcome of the upcoming court hearing on Pfizer's pre-emption defense, as a ruling against the company would significantly increase its legal and financial exposure, likely serving as a negative catalyst for the stock.
• Given the potential for a multi-billion dollar liability, it is prudent to reassess PFE's valuation to determine if this tail risk is fully priced in and consider adjusting position sizes or implementing hedging strategies to mitigate downside.
• The concurrent investigation into the board's fiduciary duties introduces a governance risk that warrants attention, as it could signal broader risk management failures and lead to further shareholder litigation.